Dr. Fisher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
44 Binney St
D1830
Boston, MA 02115Phone+1 617-632-6844Fax+1 617-632-4422
Education & Training
- Duke University HospitalFellowship, Hematology and Medical Oncology, 1992 - 1995
- Duke University HospitalResidency, Internal Medicine, 1989 - 1992
- University of Massachusetts Medical SchoolClass of 1989
Certifications & Licensure
- MA State Medical License 1994 - 2026
- NH State Medical License 2009 - 2025
- NC State Medical License 1991 - 1998
- American Board of Internal Medicine Hematology
Publications & Presentations
PubMed
- Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma.Francine M Foss, Youn H Kim, H Miles Prince, Oleg E Akilov, Christiane Querfeld
Journal of Clinical Oncology. 2025-04-01 - A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas.Mwanasha H Merrill, Robert A Redd, David C Fisher, Jeremy S Abramson, Jeffrey Barnes
Leukemia & Lymphoma. 2025-03-25 - Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.Matthew S Davids, Christine E Ryan, Benjamin L Lampson, Yue Ren, Svitlana Tyekucheva
Journal of Clinical Oncology. 2025-03-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: